|
| Activity | Compound | Clinical trial |
|
| Inhibitors of β-secretase | (i) E2609
(ii) MK-8931
(iii) LY2886721 | (i) NCT01600859
(ii) NCT01739348
(iii) NCT01807026 and NCT01561430 |
|
| Inhibitors and modulators of γ-secretase | (i) Semagacestat (LY450139)
(ii) Avagacestat | (i) NCT00762411, NCT01035138, and NCT00762411
(ii) NCT00810147, NCT00890890, NCT00810147, NCT01079819 |
|
| Selective γ-secretase modulators (SGSM) | (i) Ibuprofen, sulindac, indomethacin, and R-flurbiprofen (Tarenflurbil)
(ii) NIC5-15 | NCT00322036, NCT00105547 |
|
| Nonsteroidal inhibitory of cyclooxygenase activity (NSAIDs) | CHF5074 | NCT01203384, NCT01303744, NCT00954252 |
|
| Inhibitors of Aβ aggregation | (i) Glycosaminoglycans 3-amino acid, 1-propanesulfonic synthetic (3APS, Alzhemed, tramiprosate)
(ii) Colostrinin
(iii) Scyllo-inositol compound (ELND005)
(iv) PBT1 (clioquinol) and PBT2 | Phase III in 2007 |
|
| Modulation of β-amyloid transport from the brain to the peripheral circulation | (i) PF-0449470052
(ii) TTP4000 (NCT01548430) | (i) Phase II
(ii) Phase I (February 2013) |
|
| Active immunotherapy | (i) Anti-Aβ42 vaccine (AN1792)
(ii) CAD 106
(iii) ACC-001
(iv) ACI-24, MER5101 and AF205
(v) Bapineuzumab, solanezumab
(vi) Gantenerumab
(vii) Crenezumab (MABT5102A)
(viii) Ponezumab (PF-04360365)
(ix) MABT5102A, GSK933776A, NI-101, SAR-228810 and BAN-2401
(x) Gammagard | (i) Phase II
(ii) NCT01284387, NCT00479557 and phase II NCT01227564 (rejected)
(iii) Preclinical
(iv) NCT01127633, NCT02008357 and NCT01900665 phase III (2012)
(v) NCT01760005, NCT02051608 and NCT01224106 phase III
(vi) NCT01343966, NCT01998841 phase II (April 2013)
(vii) Phase I
(viii) NCT00818662 |
|
